Nanoparticle-Mediated Targeting of Cyclosporine A Enhances Cardioprotection Against Ischemia-Reperfusion Injury Through Inhibition of Mitochondrial Permeability Transition Pore Opening

Myocardial ischemia-reperfusion (IR) injury limits the therapeutic effects of early reperfusion therapy for acute myocardial infarction (MI), in which mitochondrial permeability transition pore (mPTP) opening plays a critical role. Our aim was to determine whether poly-lactic/glycolic acid (PLGA) nanoparticle-mediated mitochondrial targeting of a molecule that inhibits mPTP opening, cyclosporine A (CsA), enhances CsA-induced cardioprotection. In an in vivo murine IR model, intravenously injected PLGA nanoparticles were located at the IR myocardium mitochondria. Treatment with nanoparticles incorporated with CsA (CsA-NP) at the onset of reperfusion enhanced cardioprotection against IR injury by CsA alone (as indicated by the reduced MI size at a lower CsA concentration) through the inhibition of mPTP opening. Left ventricular remodeling was ameliorated 28 days after IR, but the treatment did not affect inflammatory monocyte recruitment to the IR heart. In cultured rat cardiomyocytes in vitro, mitochondrial PLGA nanoparticle-targeting was observed after the addition of hydrogen peroxide, which represents oxidative stress during IR and was prevented by CsA. CsA-NP can be developed as an effective mPTP opening inhibitor and may protect organs from IR injury.

• Publication year

  2016

• Venue

  Scientific Reports

• Publication date

  2016-02-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/srep20467PMID 26861678PMCID 4748220
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cyclosporine before PCI in Patients with Acute Myocardial Infarction.

  2015cited by this paper
• Nanoparticle-Mediated Delivery of Pitavastatin Inhibits Atherosclerotic Plaque Destabilization/Rupture in Mice by Regulating the Recruitment of Inflammatory Monocytes

  2014cited by this paper
• Massive palmitoylation-dependent endocytosis during reoxygenation of anoxic cardiac muscle

  2013cited by this paper
• Pitavastatin-incorporated nanoparticle-eluting stents attenuate in-stent stenosis without delayed endothelial healing effects in a porcine coronary artery model.

  2013cited by this paper
• Cannabinoid receptor CB2 protects against balloon-induced neointima formation.

  2012cited by this paper
• Engineering of blended nanoparticle platform for delivery of mitochondria-acting therapeutics

  2012cited by this paper
• Recombinant mitochondrial transcription factor A protein inhibits nuclear factor of activated T cells signaling and attenuates pathological hypertrophy of cardiac myocytes.

  2012cited by this paper
• Mitochondrial ROMK Channel Is a Molecular Component of MitoKATP

  2012cited by this paper
• Functionalized nanosystems for targeted mitochondrial delivery.

  2012cited by this paper
• Nanoparticle-Mediated Delivery of Pioglitazone Enhances Therapeutic Neovascularization in a Murine Model of Hindlimb Ischemia

  2012cited by this paper
• MARCKS protein mediates hydrogen peroxide regulation of endothelial permeability

  2012cited by this paper
• PLGA-based nanoparticles: an overview of biomedical applications.

  2012cited by this paper
• Therapeutic siRNA silencing in inflammatory monocytes

  2011cited by this paper
• Modulation of Na(+)-K(+)-ATPase cell surface abundance through structural determinants on the α1-subunit.

  2011cited by this paper
• PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect.

  2011cited by this paper
• Nanoparticle-Mediated Delivery of Pitavastatin Into Lungs Ameliorates the Development and Induces Regression of Monocrotaline-Induced Pulmonary Artery Hypertension

  2011cited by this paper
• Nanoparticle-mediated endothelial cell-selective delivery of pitavastatin induces functional collateral arteries (therapeutic arteriogenesis) in a rabbit model of chronic hind limb ischemia.

  2010cited by this paper
• Silent Information Regulator 1 Protects the Heart From Ischemia/Reperfusion

  2010cited by this paper
• Effect of cyclosporine on left ventricular remodeling after reperfused myocardial infarction.

  2010cited by this paper
• Integrative Physiology/Experimental Medicine Therapeutic Neovascularization by Nanotechnology- Mediated Cell-Selective Delivery of Pitavastatin Into the Vascular Endothelium

  2009cited by this paper
• Why do we still not have cardioprotective drugs?

  2009cited by this paper
• Effect of cyclosporine on reperfusion injury in acute myocardial infarction.

  2008cited by this paper
• Limitation of myocardial infarct size in the clinical setting: current status and challenges in translating animal experiments into clinical therapy

  2008cited by this paper
• Local Delivery of Imatinib Mesylate (STI571)–Incorporated Nanoparticle Ex Vivo Suppresses Vein Graft Neointima Formation

  2008cited by this paper
• Myocardial reperfusion injury.

  2007cited by this paper
• Biodegradable nanoparticles for cytosolic delivery of therapeutics.

  2007cited by this paper
• Stent-Based Local Delivery of Nuclear Factor-&kgr;B Decoy Attenuates In-Stent Restenosis in Hypercholesterolemic Rabbits

  2006cited by this paper
• Mitochondrial permeability transition pore and postconditioning.

  2006cited by this paper
• Erythropoietin protects cardiomyocytes from apoptosis via up-regulation of endothelial nitric oxide synthase.

  2006cited by this paper
• Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death

  2005cited by this paper
• Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death

  2005cited by this paper
• Glycogen synthase kinase-3β mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore

  2004cited by this paper
• Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore.

  2004cited by this paper
• Myocardial Reperfusion Injury

  2004cited by this paper
• Cyclosporin A inhibits cardiac hypertrophy and enhances cardiac dysfunction during postinfarction failure in rats.

  2000cited by this paper
• Reactive Oxygen Species (Ros-Induced) Ros Release

  2000cited by this paper
• Dose-dependent pharmacokinetics of cyclosporin A in rats: events in tissues.

  2000cited by this paper
• Functional coronary microvascular injury evident as increased permeability due to brief ischemia and reperfusion.

  1990cited by this paper

• Mitochondrial permeability transition pore desensitization by a novel dispiranic derivative prevents cardiac reperfusion injury.

  2026cites this paper
• Signaling Mechanisms of Cardioprotection and Targeted Delivery of Cardioprotective Substances to the Myocardium to Prevent Reperfusion Injury

  2025cites this paper
• Mitochondrial permeability transition pore (mPTP) as a target for drug delivery systems: challenges and opportunities

  2025cites this paper
• Nanomedicines Against Mitochondrial Dysfunction‐Induced Metabolic Diseases

  2025cites this paper
• Squalene-adenosine nanoparticles enhance cardioprotection in myocardial infarction: Efficacy and mechanistic insights.

  2025cites this paper
• Extracellular Vesicles in Cardiovascular Diseases: Signaling, Biomarker, and Therapy

  2025cites this paper
• Nanodrug targeting for myocardial ischemia-reperfusion injury: mechanisms, therapeutic strategies, and challenges in clinical translation.

  2025cites this paper
• Calcium signaling dysregulation in rheumatoid arthritis: a comparative perspective with osteoarthritis.

  2025cites this paper
• The Mitochondrial Permeability Transition Pore in Platelets: Mechanisms, Physiological Roles, and Therapeutic Perspectives

  2025cites this paper
• Nanosystems for myocardial ischemic injury theranostics.

  2025cites this paper
• Mitochondrial targets in ischaemic heart disease and heart failure, and their potential for a more efficient clinical translation. A scientific statement of the ESC Working Group on Cellular Biology of the Heart and the ESC Working Group on Myocardial Function

  2025cites this paper
• A Spotlight on PLGA-Based Nanoparticles: Pioneering a New Era in the Therapeutics of Cardiovascular Disorders.

  2025cites this paper
• Cyclophilin D plays a critical role in the survival of senescent cells

  2024cites this paper
• Essential information about nanotechnology in cardiology

  2024cites this paper
• Exploring the mechanism of Phyllanthus urinaria L. against ulcerative colitis based on network pharmacology and in vivo experiments

  2024cites this paper
• From dysfunction to healing: advances in mitochondrial therapy for Osteoarthritis

  2024cites this paper
• Modulation of mitochondrial permeability transition pores in reperfusion injury: Mechanisms and therapeutic approaches

  2024cites this paper
• Nanomedicines as Guardians of the Heart: Unleashing the Power of Antioxidants to Alleviate Myocardial Ischemic Injury

  2024cites this paper
• Applications of Nanotechnology in the Field of Cardiology

  2024cites this paper
• A bibliography of smart nanomaterials biological application in myocardial infarction research

  2024cites this paper
• Nanoparticle-based therapeutic strategies for mitochondrial dysfunction in cardiovascular disease.

  2024cites this paper
• Multiple delivery strategies of nanocarriers for myocardial ischemia-reperfusion injury: current strategies and future prospective

  2023influential citation
• Nanoparticle Based Cardiac Specific Drug Delivery

  2023cites this paper
• Precision medicine in myocardial infarction: Nanotheranostic strategies

  2023cites this paper
• Mitochondria-targeted nanomedicines for cardiovascular applications.

  2023cites this paper
• Nanoparticles for targeted drug delivery in modern cardiology

  2023cites this paper
• Nanotechnology in Coronary Heart Disease.

  2023cites this paper
• An Overview of Nanomaterial Applications in Pharmacology

  2023cites this paper
• Nanomaterials-based imaging diagnosis and therapy of cardiovascular diseases

  2022cites this paper
• Extrahepatic targeting of lipid nanoparticles in vivo with intracellular targeting for future nanomedicines.

  2022cites this paper
• Role of Nanotechnology and Their Perspectives in the Treatment of Kidney Diseases

  2022cites this paper
• Dietary 7-ketocholesterol exacerbates myocardial ischemia–reperfusion injury in mice through monocyte/macrophage-mediated inflammation

  2022cites this paper
• Tregs biomimetic nanoparticle to reprogram inflammatory and redox microenvironment in infarct tissue to treat myocardial ischemia reperfusion injury in mice

  2022cites this paper
• Mitochondrial Dysfunction in Cardiovascular Diseases: Potential Targets for Treatment

  2022cites this paper
• Mitochondrial Ca2+ Homeostasis: Emerging Roles and Clinical Significance in Cardiac Remodeling

  2022cites this paper
• Nanoparticles Based on Cross-Linked Poly(Lipoic Acid) Protect Macrophages and Cardiomyocytes from Oxidative Stress and Ischemia Reperfusion Injury

  2022cites this paper
• Dietary 7-ketocholesterol exacerbates myocardial ischemia–reperfusion injury in mice through monocyte/macrophage-mediated inflammation

  2022cites this paper
• Gene Therapy for Cardiomyocyte Renewal: Cell Cycle, a Potential Therapeutic Target

  2022cites this paper
• Recent advances in nanomedicines for imaging and therapy of myocardial ischemia-reperfusion injury.

  2022cites this paper
• The Therapeutic Strategies Targeting Mitochondrial Metabolism in Cardiovascular Disease

  2022cites this paper
• Perspectives on mitochondrial relevance in cardiac ischemia/reperfusion injury

  2022cites this paper
• Preclinical systematic review & meta-analysis of cyclosporine for the treatment of myocardial ischemia-reperfusion injury

  2022cites this paper
• Nanoparticle‐Mediated Simultaneous Targeting of Mitochondrial Injury and Inflammation Attenuates Myocardial Ischemia‐Reperfusion Injury

  2021cites this paper
• New Nanoparticle Formulation for Cyclosporin A: In Vitro Assessment

  2021cites this paper
• S-allylcysteine improves ischemia/reperfusion alteration on cardiac function, antioxidant, and mitochondrial permeability.

  2021cites this paper
• Bisindolylpyrrole Induces a Cpr3- and Porin1/2-Dependent Transition in Yeast Mitochondrial Permeability in a Low Conductance State via the AACs-Associated Pore

  2021cites this paper
• Insights into the modulatory role of cyclosporine A and its research advances in acute inflammation.

  2021cites this paper
• Endogenous asymmetric dimethylarginine accumulation precipitates the cardiac and mitochondrial dysfunctions in type 1 diabetic rats.

  2021cites this paper
• Targeting fibrosis in the failing heart with nanoparticles.

  2021cites this paper
• Role of Oxidative Stress in Reperfusion following Myocardial Ischemia and Its Treatments

  2021cites this paper
• The mitochondrial permeability transition pore: an evolving concept critical for cell life and death

  2021cites this paper
• Mitochondrial nanomedicine: Subcellular organelle-specific delivery of molecular medicines.

  2021cites this paper
• Repurpose but also (nano)-reformulate! The potential role of nanomedicine in the battle against SARS-CoV2

  2021cites this paper
• Advance cardiac nanomedicine by targeting the pathophysiological characteristics of heart failure.

  2021cites this paper
• Animal models used in the research of nanoparticles for cardiovascular diseases

  2021cites this paper
• Therapeutic potential and recent advances on targeting mitochondrial dynamics in cardiac hypertrophy: A concise review

  2021cites this paper
• Nanomaterials aimed toward the cardiac mitochondria: from therapeutics to nanosafety

  2021cites this paper
• Nanoparticles: Promising Tools for the Treatment and Prevention of Myocardial Infarction

  2021cites this paper
• Mitochondria‐targeted nanoparticles in treatment of neurodegenerative diseases

  2021cites this paper
• Use of nanoscale-delivery systems in tissue/organ regeneration

  2020cites this paper
• Nanoparticle delivery of cardioprotective therapies.

  2020cites this paper
• Mitochondria as a therapeutic target for cardiac ischemia-reperfusion injury (Review)

  2020cites this paper
• A Phenyl-Pyrrolidine Derivative Reveals a Dual Inhibition Mechanism of Myocardial Mitochondrial Permeability Transition Pore, Which Is Limited by Its Myocardial Distribution

  2020cites this paper
• Mitochondria-Targeted Drug Delivery in Cardiovascular Disease: A Long Road to Nano-Cardio Medicine

  2020influential citation
• Simultaneous targeting of mitochondria and monocytes enhances neuroprotection against ischemia–reperfusion injury

  2020cites this paper
• Mitochondria in acute myocardial infarction and cardioprotection

  2020cites this paper
• Nanoparticle-Mediated Drug Delivery for Treatment of Ischemic Heart Disease

  2020cites this paper
• Nanoparticle-Mediated Drug Delivery for the Treatment of Cardiovascular Diseases

  2020cites this paper
• Isovaleroylbinankadsurin A ameliorates cardiac ischemia/reperfusion injury through activating GR dependent RISK signaling.

  2020cites this paper
• Amorphous SiO2 nanoparticles promote cardiac dysfunction via the opening of the mitochondrial permeability transition pore in rat heart and human cardiomyocytes

  2020cites this paper
• Ischemia/Reperfusion Injury Revisited: An Overview of the Latest Pharmacological Strategies

  2019cites this paper
• An innovative sequence of hypoxia-reoxygenation on adult mouse cardiomyocytes in suspension to perform multilabeling analysis by flow cytometry.

  2019cites this paper
• A novel class of cardioprotective small-molecule PTP inhibitors.

  2019cites this paper
• Protective effect of cyclosporine A in the treatment of severe hydronephrosis in a rabbit renal pelvic perfusion model

  2019cites this paper
• Nanoscale Technologies for Prevention and Treatment of Heart Failure: Challenges and Opportunities.

  2019cites this paper
• Hurdles to Cardioprotection in the Critically Ill

  2019cites this paper
• Nanoencapsulated Quercetin Improves Cardioprotection during Hypoxia-Reoxygenation Injury through Preservation of Mitochondrial Function

  2019cites this paper
• Innovation in nanomedicine and engineered nanomaterials for therapeutic purposes

  2019cites this paper
• The greater effect of high-intensity interval training versus moderate-intensity continuous training on cardioprotection against ischemia-reperfusion injury through Klotho levels and attenuate of myocardial TRPC6 expression

  2019cites this paper
• Autophagy, Apoptosis, and Mitochondria: Molecular Integration and Physiological Relevance in Skeletal Muscle.

  2019cites this paper
• Nanoparticle incorporating Toll-like receptor 4 inhibitor attenuates myocardial ischaemia-reperfusion injury by inhibiting monocyte-mediated inflammation in mice.

  2019cites this paper
• Depression and the risk of rheumatoid arthritis

  2019cites this paper
• Safety, Tolerability, and Pharmacokinetics of NK-104-NP.

  2018cites this paper
• Targeting mitochondria for cardiovascular disorders: therapeutic potential and obstacles

  2018cites this paper
• Pretreatment with Total Flavonoid Extract from Dracocephalum Moldavica L. Attenuates Ischemia Reperfusion-induced Apoptosis

  2018cites this paper
• Nanoparticle-Mediated Targeting of Pitavastatin to Small Pulmonary Arteries and Leukocytes by Intravenous Administration Attenuates the Progression of Monocrotaline-Induced Established Pulmonary Arterial Hypertension in Rats.

  2018cites this paper
• A Multicenter, Randomized, Placebo-Controlled Phase I Investigator-Initiated Trial for Intravenous Administration of Pitavastatin-Loaded PLGA Nanoparticles (NK-104-NP) in Healthy Japanese Male Subjects

  2018cites this paper
• Pharmacological Targeting of the Mitochondrial Permeability Transition Pore for Cardioprotection

  2018cites this paper
• Polyelectrolyte-coated nanocapsules containing cyclosporine A protect neuronal-like cells against oxidative stress-induced cell damage

  2018cites this paper
• Mitophagy in Cardiomyocytes and in Platelets: A Major Mechanism of Cardioprotection Against Ischemia/Reperfusion Injury.

  2018cites this paper
• Heart tissue repair and cardioprotection using drug delivery systems.

  2018cites this paper
• Mitochondria in Structural and Functional Cardiac Remodeling.

  2017cites this paper
• Targeting mitochondrial permeability as a pharmacological cardioprotective strategy.

  2017cites this paper
• Nanoparticle-Mediated Endothelial Cell-Selective Drug Delivery System

  2017cites this paper
• Nanomedicine for the cardiac myocyte: Where are we?

  2017influential citation
• New and revisited approaches to preserving the reperfused myocardium

  2017cites this paper
• Nanoparticle-mediated drug delivery system for atherosclerotic cardiovascular disease.

  2017cites this paper
• Biochemical targets of drugs mitigating oxidative stress via redox-independent mechanisms.

  2017cites this paper
• Nanoparticle-Mediated Delivery of Pitavastatin to Monocytes/Macrophages Inhibits Left Ventricular Remodeling After Acute Myocardial Infarction by Inhibiting Monocyte-Mediated Inflammation.

  2017cites this paper
• A Mechanism Study Underlying the Protective Effects of Cyclosporine-A on Lung Ischemia-Reperfusion Injury

  2017cites this paper